Seattle Genetics Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Seattle Genetics Inc Stock Forecast and Price Target
The average target price for Seattle Genetics Inc's stock set by renowned analysts in recent months is $229.00, representing a potential upside of approximately 0.11% from its last closing price if met by 2025. This estimation is based on a high estimate of $229.00 and a low estimate of $229.00. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
0.11% Upside
Seattle Genetics Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Seattle Genetics Inc's Price has seen a drop from $48.90 to $0.00 – a 100.00% decrease. In the next year, analysts predict that Fair Value will reach $246.23 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.80 | Buy/Sell | $178.42 | 12.63% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$273.01 | Buy/Sell | $303.65 | 16.20% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.08 | Buy/Sell | $87.82 | 19.26% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$201.99 | Buy/Sell | $299.62 | 41.10% |
Seattle Genetics Inc Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Seattle Genetics Inc's Revenue has seen a drop from $2.18B to $1.96B – a 9.80% decrease. In the next year, analysts predict that Revenue will reach $3.16B – an increase of 61.07%. For the next seven years, the forecast is for Revenue to grow by 361.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$91.20 | Buy/Sell | $111.56 | 20.07% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.74 | Buy/Sell | $77.05 | 49.21% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$92.26 | Buy/Sell | $85.71 | 8.39% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.54 | Buy/Sell | $17.90 | 89.75% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$65.07 | Buy/Sell | $34.00 | 76.73% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.71 | Buy/Sell | $20.42 | 117.76% |
Seattle Genetics Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Seattle Genetics Inc's EBITDA has decreased from $649.24M to $-543.17M – a 183.66% drop. In the following year, 3 experts forecast that Seattle Genetics Inc's EBITDA will decrease by 37.84%, to $-337.61M. In 2030, professionals predict that Seattle Genetics Inc's EBITDA will decrease by 416.96%, to $1.72B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$16.59 | Buy/Sell | $33.78 | 80.83% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.29 | Buy/Sell | $52.00 | 127.57% |
Seattle Genetics Inc EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Seattle Genetics Inc's EBIT has decreased by 202.70%, going from $596.85M to $-612.97M. 17 analysts predict Seattle Genetics Inc's EBIT will decrease by 78.16% in the next year, reaching $-133.87M. By 2030, professionals predict that Seattle Genetics Inc's EBIT will decrease by 763.72%, to $4.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$37.02 | Buy/Sell | $63.29 | 108.00% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.11 | Buy/Sell | $42.58 | 19.28% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.43 | Buy/Sell | $9.94 | 117.73% |
Seattle Genetics Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Seattle Genetics Inc's EPS has seen a drop from $3.26 to $0.00 – a 100.00% decrease. In the next year, analysts predict that EPS will reach $-0.75 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.42 | Buy/Sell | $25.00 | 114.54% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$31.67 | Buy/Sell | $40.00 | 37.35% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.46 | Buy/Sell | $6.00 | 23.84% |
.jpg)